Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 6 de 6
Filtrer
2.
Clin Infect Dis ; 50(11): e63-8, 2010 Jun 01.
Article de Anglais | MEDLINE | ID: mdl-20420515

RÉSUMÉ

We describe 3 cases of daptomycin-induced pulmonary toxic effects that are consistent with drug-induced acute eosinophilic pneumonia. Patients presented similarly with dyspnea, cough, hypoxia, and diffuse ground-glass opacities at chest computed tomography. Clinical suspicion for this adverse drug event and cessation of daptomycin until definitive diagnosis can be made is crucial.


Sujet(s)
Antibactériens/effets indésirables , Daptomycine/effets indésirables , Poumon éosinophile/induit chimiquement , Poumon éosinophile/diagnostic , Sujet âgé de 80 ans ou plus , Humains , Mâle , Adulte d'âge moyen , Poumon éosinophile/anatomopathologie , Radiographie thoracique , Tomographie
3.
Crit Care ; 12(5): 233, 2008.
Article de Anglais | MEDLINE | ID: mdl-18983709

RÉSUMÉ

Antipseudomonal carbapenems have played a useful role in our antimicrobial armamentarium for 20 years. However, a review of their use during that period creates concern that their clinical effectiveness is critically dependent on attainment of an appropriate dosing range. Unfortunately, adequate carbapenem dosing is missed for many reasons, including benefit/risk misconceptions, a narrow therapeutic window for imipenem and meropenem (due to an increased rate of seizures at higher doses), increasingly resistant pathogens requiring higher doses than are typically given, and cost containment issues that may limit their use. To improve the use of carbapenems, several initiatives should be considered: increase awareness about appropriate treatment with carbapenems across hospital departments; determine optimal dosing regimens for settings where multidrug resistant organisms are more likely encountered; use of, or combination with, an alternative antimicrobial agent having more favorable pharmacokinetic, pharmacodynamic, or adverse event profile; and administer a newer carbapenem with lower propensity for resistance development (for example, reduced expression of efflux pumps or greater stability against carbapenemases).


Sujet(s)
Antibactériens/effets indésirables , Antibactériens/usage thérapeutique , Carbapénèmes/effets indésirables , Carbapénèmes/usage thérapeutique , Infections à Pseudomonas/traitement médicamenteux , Infections à Pseudomonas/économie , Pseudomonas aeruginosa , Animaux , Antibactériens/économie , Antibactériens/pharmacologie , Carbapénèmes/économie , Carbapénèmes/pharmacologie , Essais cliniques comme sujet/effets indésirables , Essais cliniques comme sujet/économie , Humains , Pseudomonas aeruginosa/effets des médicaments et des substances chimiques
4.
Crit Care ; 12 Suppl 4: S4, 2008.
Article de Anglais | MEDLINE | ID: mdl-18495061

RÉSUMÉ

Resistance rates are increasing among several problematic Gram-negative pathogens that are often responsible for serious nosocomial infections, including Acinetobacter spp., Pseudomonas aeruginosa, and (because of their production of extended-spectrum beta-lactamase) Enterobacteriaceae. The presence of multiresistant strains of these organisms has been associated with prolonged hospital stays, higher health care costs, and increased mortality, particularly when initial antibiotic therapy does not provide coverage of the causative pathogen. Conversely, with high rates of appropriate initial antibiotic therapy, infections caused by multiresistant Gram-negative pathogens do not negatively influence patient outcomes or costs. Taken together, these observations underscore the importance of a 'hit hard and hit fast' approach to treating serious nosocomial infections, particularly when it is suspected that multiresistant pathogens are responsible. They also point to the need for a multidisciplinary effort to combat resistance, which should include improved antimicrobial stewardship, increased resources for infection control, and development of new antimicrobial agents with activity against multiresistant Gram-negative pathogens.


Sujet(s)
Antibactériens/usage thérapeutique , Infections bactériennes à Gram négatif/traitement médicamenteux , Antibactériens/économie , Infection croisée/traitement médicamenteux , Infection croisée/économie , Résistance bactérienne aux médicaments , Multirésistance aux médicaments , Bactéries à Gram négatif/effets des médicaments et des substances chimiques , Infections bactériennes à Gram négatif/économie , Humains , Tests de sensibilité microbienne , Facteurs de risque
5.
Am J Med ; 118 Suppl 7A: 1S-6S, 2005 Jul.
Article de Anglais | MEDLINE | ID: mdl-15993671

RÉSUMÉ

In response to the overuse and misuse of antibiotics, leading to increasing bacterial resistance and decreasing development of new antibiotics, the Council for Appropriate and Rational Antibiotic Therapy (CARAT) has developed criteria to guide appropriate and accurate antibiotic selection. The criteria, which are aimed at optimizing antibiotic therapy, include evidence-based results, therapeutic benefits, safety, optimal drug for the optimal duration, and cost-effectiveness.


Sujet(s)
Antibactériens/administration et posologie , Infections bactériennes/traitement médicamenteux , Utilisation médicament/normes , Antibactériens/économie , Antibactériens/pharmacocinétique , Analyse coût-bénéfice , Humains , Sélection de patients
6.
J Fam Pract ; Suppl: S15-7, 2005 Jun.
Article de Anglais | MEDLINE | ID: mdl-15938990

RÉSUMÉ

Identification of risk factors present in the medical history should alert physicians to patients at potentially high risk for drug-induced QT interval prolongation. Careful patient monitoring and treatment adjustment will aid physicians in avoiding the complications of QT interval prolongation.


Sujet(s)
Syndrome du QT long/prévention et contrôle , Antiarythmiques/effets indésirables , Électrocardiographie , Femelle , Humains , Syndrome du QT long/induit chimiquement , Syndrome du QT long/diagnostic , Mâle , Recueil de l'anamnèse , Appréciation des risques/méthodes , Facteurs de risque
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE